Final Opportunity to Invest in FemTech III –
Fund Closing Soon
The FemTech III Fund is rapidly approaching its maximum number of investors and will be closing to new investments soon. This is your last opportunity to be part of this fund that is shaping the future of women’s health and delivering strong returns.
Don’t miss out on this unique opportunity to invest in women’s health —secure your place in FemTech III before it closes to new investors!
Highlights on the importance of Investing in Women’s Health
About FemTech Fund III
Portfolia is the most active investor in women's health in the US, with 50+ investments in fast-growth women’s health companies, from seed stage to pre-IPO. Investments include early-stage companies like Bone Health and Your Choice to fast scaling brand-name companies, like unicorns Everly Health and Maven Clinic. The Portfolia FemTech III Fund builds on Portfolia’s global brand in women's health, optimizing returns and enhancing the health and wellness of women.
Portfolia raised the world's first venture capital fund focused exclusively in women's health in 2018, and has the most robust pipeline of investment opportunities in the field. We are the experts in scaling women’s health companies, for outsized returns and impact. McKinsey has sized the investment opportunity in women’s health at $1 trillion dollars. Portfolia Funds are best positioned to continue to lead in selecting and growing the innovative companies in women’s health for the world.
“Portfolia is the leading investor in women’s health in the US, with
50+ investments in healthcare companies.”
OUR FEMTECH III INVESTMENTS
Apollo Neuro is a wearable consumer wellness device intended to help manage stress, challenging life transitions, and to promote a healthy lifestyle.
Attn Grace is a sustainable wellness brand creating more sustainable solutions for women to combat bladder leakage.
Maude is a retailer of essential sexual wellness products improving intimate experiences.
Using its AI epigenetics platform to detect dysregulation across genes and pioneering a new category of diagnostics to transform diagnoses starting with infertility.
FEMDX is a developer of cancer diagnosis devices designed to detect ovarian cancer.
Simple Health Kit provides high-quality, accessible, and affordable diagnostic services for chronic health conditions.
Neuspera develops ultra-miniaturized, implantable medical devices for treating chronic conditions such as Overactive Bladder (OAB).
Our Focus Areas
Portfolia goes beyond, the obvious investments in menstrual care, fertility solutions and pregnancy care have received the most significant investments, into all facets of women's health and wellness at every stage of life. Portfolia will consider companies in the following areas, but not limited to:
Women-specific Conditions: Contraception, Fertility, Maternal Health, Menopause, Gynecology & Women’s Oncology
Conditions that Affect Women Differently: Cardiovascular Disease, Diabetes, Alzheimer’s Disease
Conditions that Affect Women Disproportionally: Autoimmune Disease, Osteoporosis, Anxiety and Depression, Lung Cancer, Eating Disorders
Conditions Characterized by Gender-based Discrepancies in care: Pain Management, Behavioral Health, Addiction
Racial disparities and inequities in women's health: Conditions that affect women of color differently, access to care, quality of care, lack of culturally competent care providers, systemic racism
FEMTECH COMPANIES IN THE NEWS
FEMTECH FUND III PARTNERS
An anchor tenet of venture capital when evaluating investments is that it is always about the team. In the case of FemTech III, the partners are the most experienced investors in women’s health, across stages and specialty focus, and the fund is recognized as a global expert in this space. Collectively this competitive advantage means:
Deep and rich sourcing networks bringing a robust pipeline of women entrepreneurs and their growing company.
A global network of business building experts across every stage and specialty field in fast growth entrepreneurship
Vast global intelligence for due diligence and decision-making, and an early-warning system for competition and problem solving
Predictive knowledge regarding emerging needs as entrepreneurs scale their companies, resulting in better strategies, hiring and fundraising
Advisory assistance and C-suite and team coaching
Dr. Faz Bashi
FemTech I, II & III
Investment Lead: Future Family, Maven Clinic, Joylux, Nest Collaborative
Founding Member, Healthtech Capital
Angel Capital Association Life Sciences Syndication Group Chair
Angel Capital Assoc Bd of Dir
Lauri Kien Kotcher
FemTech II & III
Investment Lead: Attn: Grace, Hey Jane, Madison Reed
Former CEO of Hello Products
Former CMO of Godiva
Former Head of Global Brands at Pfizer Consumer Healthcare.
Advisory board member, Springboard Enterprises & The New York Fashion Tech Lab
Jennifer Fried
FemTech I, II & III
Investment Lead: Willow, YourChoice, Proov, Aria CV
Founder and/or CEO of multiple medical device companies
Previously Partner at Park Lane Ventures, healthcare-focused fund
Kauffman Fellow
Nola Masterson
FemTech I,II & III
Investment Lead: Aeena, Bone Health Technologies, Inherent Biosciences, xCures
California Life Sciences Institute, Chair Emeritus
Co-Founder and first CEO of Sequenom
45+ years in the life sciences industry and in venture investments
Delphine O’Rourke
FemTech III
Leader & expert in women’s health industry innovation, law & investment
Columbia Law School, Adjunct Professor
Boards of medical device, digital health, care delivery, SaaS companies in women's health
Previously Partner & Chair, Women's Health & Wellness Industry Practice, at Goodwin Procter
Former Associate General Counsel, Ascension
WHY INVEST IN FEMTECH NOW?
Traditionally, women’s health investment and research has been woefully underfunded. This is rapidly changing, and Portfolia is leading the way. Less than 2% of federal medical research had been invested in women’s health and until quite recently, women were systematically left out of research protocols. Today an additional $1 Billion has been committed to women’s health research opening up new innovations and opportunities for investment.
Venture capitalists are the ones that ‘greenlight’ and fund the latest healthcare technologies post research, but because women make up only 2% of VC investing partners, women’s health investments were rarely understood or appreciated for potential returns or impact. Portfolia has changed this dynamic, aggregating tens of millions of dollars of women’s investment capital and focusing our dollars and expertise in the growth and success of these companies.
The result is outsized financial returns for women and better health and wellness for ourselves, our children, and generations to come. Investing is where change happens.
Investments in women’s health is a $1 trillion opportunity.
2024 is on pace to become a top three funding year for the women's health sector.
$435M Investments in non-fertility startups in Q3 2023
This single quarter record shows a heartening shift in the long-held misconception that fertility and pregnancy are the sole focus of women’s health.
